fashion -WSS

fashion

author：knowledge 2025-09-04 05:36:42 - browse：9

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： FDA endorses new sterilization method for medical devices

hotspot

focus

WSS

TikTok, Instagram influencers need more rules for drug ads

FDA endorses new sterilization method for medical devices

Future doctors need a strong humanities education

Why hospitals are withdrawing from US News rankings

HPV vaccine, cervical cancer study delivers historic results

Cosmetics set for new safety regulation. Why the industry is on board

hotspot

fashion

leisure time

Hollywood unions extend contract negotiations for actors

What causes osteoarthritis? Researchers study link to brain protein

At least 13 dead in Texas as scorching temps continue

There's an unseen cost to disruptive road

ChatGPT in medicine: STAT answers readers' burning questions

Mass General, Mayo Clinic look to monetize custom

Dobbs anniversary: the lost opportunity of abortion as health care

Dog Aging Project founders on what lies ahead after losing funding

Tori Bowie and the unacceptable rates of Black maternal death

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

focus

Biden tests positive for Covid

Group opposing PBM reform sets lobbying record

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

There's an unseen cost to disruptive road

Head of FDA's diagnostics center, who led through Covid, retires

Immunocompromised patients offer clues on chronic Covid

hotspot

focus

Wikipedia

hotspot